Kaleeckal, Anvar Hassan

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections

Altarawneh, H. N., Chemaitelly, H., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Coyle, P., Al-Kanaani, Z., et al. (2022) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 551

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

Tang, P., Hasan, M. R., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., AlMukdad, S., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 450

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Malek, J. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 386

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar

Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Tang, P., Hasan, M. R., Coyle, P., et al. (2022) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 380

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., et al. (2022) · Nature Communications

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 228

SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks

Abu-Raddad, L. J., Chemaitelly, H., Coyle, P., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., Younuskunju, S., Ayoub, H. H., Kanaani, Z. A., Kuwari, E. A., et al. (2021) · EClinicalMedicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 201

Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic

Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., Butt, A. A., Coyle, P., Jeremijenko, A., Kaleeckal, A. H., et al. (2021) · Scientific Reports

COVID-19 epidemiological studiesSARS-CoV-2 and COVID-19 Research

Cited by 148

Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant

Butt, A. A., Dargham, S. R., Loka, S., Shaik, R. M., Chemaitelly, H., Tang, P., Hasan, M. R., Coyle, P. V., Yassine, H. M., Al-Khatib, H. A., et al. (2022) · Clinical Infectious Diseases

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 129

Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar

Jeremijenko, A., Chemaitelly, H., Ayoub, H. H., Alishaq, M., Abou-Samra, A.-B., Al Ajmi, J. A. A. A., Al Ansari, N. A. A., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., et al. (2021) · Emerging Infectious Diseases

COVID-19 epidemiological studiesSARS-CoV-2 and COVID-19 Research

Cited by 97

Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination

Butt, A. A., Nafady-Hego, H., Chemaitelly, H., Abou-Samra, A.-B., Khal, A. A., Coyle, P. V., Kanaani, Z. A., Kaleeckal, A. H., Latif, A. N., Masalmani, Y. A., et al. (2021) · International Journal of Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 94

SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals

Coyle, P. V., Chemaitelly, H., Ben Hadj Kacem, M. A., Abdulla Al Molawi, N. H., El Kahlout, R. A., Gilliani, I., Younes, N., Al Anssari, G. A. A. A., Al Kanaani, Z., Al Khal, A., et al. (2021) · iScience

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 86

SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar

Al-Thani, M. H., Farag, E., Bertollini, R., Al Romaihi, H. E., Abdeen, S., Abdelkarim, A., Daraan, F., Elhaj Ismail, A. I. H., Mostafa, N., Sahl, M., et al. (2021) · Open Forum Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 85

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

Chemaitelly, H., Ayoub, H. H., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., Al-Kuwari, E., et al. (2022) · Nature Communications

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 84

Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19

Ayoub, H. H., Chemaitelly, H., Seedat, S., Makhoul, M., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., Butt, A. A., Coyle, P., Jeremijenko, A., et al. (2021) · Journal of Global Health

COVID-19 epidemiological studiesMathematical and Theoretical Epidemiology and Ecology Models

Cited by 81

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses

Abu-Raddad, L. J., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Malek, J. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Journal of Travel Medicine

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 76

Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study

Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., et al. (2022) · The Lancet Microbe

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 76

SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar

Seedat, S., Chemaitelly, H., Ayoub, H. H., Makhoul, M., Mumtaz, G. R., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., Butt, A. A., Coyle, P., et al. (2021) · Scientific Reports

COVID-19 Clinical Research StudiesCOVID-19 epidemiological studies

Cited by 63

Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study

Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Coyle, P., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., Younuskunju, S., Tang, P., Al Kanaani, Z., et al. (2021) · PLOS Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 54

Estimating protection afforded by prior infection in preventing reinfection: Applying the test-negative study design

Ayoub, H. H., Tomy, M., Chemaitelly, H., Altarawneh, H. N., Coyle, P., Tang, P., Hasan, M. R., Kanaani, Z. A., Kuwari, E. A., Butt, A. A., et al. (2022) · American Journal of Epidemiology

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 41

Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar

Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Tang, P., Hasan, M. R., Yassine, H. M., Khatib, H. A. A., Smatti, M. K., Coyle, P., Kanaani, Z. A., et al. (2022) · medRxiv

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 30

SARS-CoV-2 vaccine effectiveness in immunosuppressed kidney transplant recipients

Chemaitelly, H., AlMukdad, S., Joy, J. P., Ayoub, H. H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Coyle, P., et al. (2021) · medRxiv

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 12